Advertisement

Prevalence of right atrial non-pulmonary vein triggers in atrial fibrillation patients treated with thyroid hormone replacement therapy

  • Ki-Hun Kim
  • Sanghamitra Mohanty
  • Prasant Mohanty
  • Chintan Trivedi
  • Eli Hamilton Morris
  • Pasquale Santangeli
  • Rong Bai
  • Amin Al-Ahmad
  • John David Burkhardt
  • Joseph G. Gallinghouse
  • Rodney Horton
  • Javier E. Sanchez
  • Shane Bailey
  • Patrick M. Hranitzky
  • Jason Zagrodzky
  • Soo G. Kim
  • Luigi Di Biase
  • Andrea Natale
Article

Abstract

Background

Thyroid hormone (TH) is known to enhance arrhythmogenicity, and high-normal thyroid function is related with an increased recurrence of atrial fibrillation (AF) after catheter ablation. However, the impact of thyroid hormone replacement (THR) on AF ablation is not well known.

Methods

This study evaluated 1163 consecutive paroxysmal AF patients [160 (14%) on THR and 1003 (86%) without THR] undergoing their first catheter ablation. A total of 146 patients on THR and 146 controls were generated by propensity matching, based on calculated risk factor scores, using a logistic model (age, sex, body mass index, and left atrium size). The presence of non-pulmonary vein (PV) triggers was disclosed by a high-dose isoproterenol challenge (up to 30 μg/min) after PV isolation.

Results

Clinical characteristics were not different between the groups. When compared to the control, non-PV triggers were significantly greater in the THR patients [112 (77%) vs. 47 (32%), P < 0.001], and most frequently originated from the right atrium (95 vs. 56%, P < 0.001). Other sources of non-PV triggers were the interatrial septum (25 vs. 11%, P = 0.002), coronary sinus (70 vs. 52%, P = 0.01), left atrial appendage (47 vs. 34%, P = 0.03), crista terminalis/superior vena cava (11 vs. 8%, P = 0.43), and mitral valve annulus (7 vs. 5%, P = 0.45) (THR vs. control), respectively. After mean follow-up of 14.7 ± 5.2 months, success rate was lower in patients on THR therapy [94 (64.4%)] compared to patients not receiving THR therapy [110 (75.3%), log-rank test value = 0.04].

Conclusions

Right atrial non-PV triggers were more prevalent in AF patients treated with THR. Elimination of non-PV triggers provided better arrhythmia-free survival in the non-THR group.

Keywords

Atrial fibrillation Catheter ablation Thyroid hormone 

Notes

Compliance with ethical standards

Conflict of interest

Dr. Natale received speaker honorariums from Boston Scientific, Biosense Webster, St. Jude Medical, Biotronik and Medtronic; Dr. Natale is a consultant for Biosense Webster St Jude Medical and Janssen. Dr Burkhardt is a consultant for Biosense-Webster and Stereotaxis.

Dr. Di Biase is a consultant for Biosense Webster, Stereotaxis and St Jude Medical. Dr. Di Biase received speaker honoraria/travel from Medtronic, EPiEP, Janssen, Pfizer, Bristol Meyers, Boston Scientific and Biotronik.

Other authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

All patients who underwent catheter ablation provided written informed consent before the procedure.The outcome data was extracted from our prospective AFib registry, which is Institutional Review Board (IRB)-approved.

References

  1. 1.
    Bielecka-Dabrowa A, Mikhailidis DP, Rysz J, Banach M: . Thyroid Res 2009; 2:4-6614-2-4Google Scholar
  2. 2.
    Bellew SD, Moman R, Lohse CM, Hess EP, Bellolio MF. Validation of a decision rule for selective TSH screening in atrial fibrillation. West J Emerg Med. 2015;16:195–202.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Tang RB, Liu DL, Dong JZ, Liu XP, Long DY, Yu RH, et al. High-normal thyroid function and risk of recurrence of atrial fibrillation after catheter ablation. Circ J. 2010;74:1316–21.CrossRefPubMedGoogle Scholar
  4. 4.
    Selmer C, Olesen JB, Hansen ML, Lindhardsen J, Olsen AM, Madsen JC, et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ. 2012;345, e7895.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Shimizu T, Koide S, Noh JY, Sugino K, Ito K, Nakazawa H. Hyperthyroidism and the management of atrial fibrillation. Thyroid. 2002;12:489–93.CrossRefPubMedGoogle Scholar
  6. 6.
    Zhang Y, Dedkov EI, Lee 3rd B, Li Y, Pun K, Gerdes AM. Thyroid hormone replacement therapy attenuates atrial remodeling and reduces atrial fibrillation inducibility in a rat myocardial infarction-heart failure model. J Card Fail. 2014;20:1012–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Mohanty S, Mohanty P, Trivedi C, Gianni C, Bai R, Burkhardt JD, et al. Association of pretreatment with angiotensin-converting enzyme inhibitors with improvement in ablation outcome in atrial fibrillation patients with low left ventricular ejection fraction. Heart Rhythm. 2015;12:1963–71.CrossRefPubMedGoogle Scholar
  8. 8.
    Kim EJ, Lyass A, Wang N, Massaro JM, Fox CS, Benjamin EJ, et al. Relation of hypothyroidism and incident atrial fibrillation (from the Framingham Heart Study). Am Heart J. 2014;167:123–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Chaker L, Heeringa J, Dehghan A, Medici M, Visser WE, Baumgartner C, Hofman A, Rodondi N, Peeters RP, Franco OH: Normal thyroid function and the risk of atrial fibrillation: the Rotterdam study. J Clin Endocrinol Metab 2015:jc20152480Google Scholar
  10. 10.
    Nacar AB, Acar G, Yorgun H, Akcay A, Ozkaya M, Canpolat U, et al. The effect of antithyroid treatment on atrial conduction times in patients with subclinical hyperthyroidism. Echocardiogr. 2012;29:950–5.CrossRefGoogle Scholar
  11. 11.
    Chen YC, Chen SA, Chen YJ, Chang MS, Chan P, Lin CI. Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes. J Am Coll Cardiol. 2002;39:366–72.CrossRefPubMedGoogle Scholar
  12. 12.
    Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FD, Wilson S, et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med. 2007;167:928–34.CrossRefPubMedGoogle Scholar
  13. 13.
    Heeringa J, Hoogendoorn EH, van der Deure WM, Hofman A, Peeters RP, Hop WC, et al. High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study. Arch Intern Med. 2008;168(20):2219–24.CrossRefPubMedGoogle Scholar
  14. 14.
    Park YJ, Yoon JW, Kim KI, Lee YJ, Kim KW, Choi SH, et al. Subclinical hypothyroidism might increase the risk of transient atrial fibrillation after coronary artery bypass grafting. Ann Thorac Surg. 2009;87(6):1846–52.CrossRefPubMedGoogle Scholar
  15. 15.
    Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331(19):1249–52.CrossRefPubMedGoogle Scholar
  16. 16.
    Sairaku A, Nakano Y, Uchimura Y, Tokuyama T, Kawazoe H, Watanabe Y, Matsumura H, Kihara Y. Increased left atrial pressure in non-heart failure patients with subclinical hypothyroidism and atrial fibrillation. Endocr Connect. 2016.Google Scholar
  17. 17.
    Kolettis TM, Tsatsoulis A. Subclinical hypothyroidism: an overlooked cause of atrial fibrillation? JAFIB. 2013;5(4):6–8.Google Scholar
  18. 18.
    Di Biase L, Santangeli P, Burkhardt JD, Natale A. Which is the best approach for ablation of long-standing persistent atrial fibrillation? Pacing Clin Electrophysiol. 2013;36:1198–201.PubMedGoogle Scholar
  19. 19.
    Santangeli P, Di Biase L, Natale A. Ablation versus drugs: what is the best first-line therapy for paroxysmal atrial fibrillation? Antiarrhythmic drugs are outmoded and catheter ablation should be the first-line option for all patients with paroxysmal atrial fibrillation: pro. Circ Arrhythm Electrophysiol. 2014;7:739–46.CrossRefPubMedGoogle Scholar
  20. 20.
    Natale A, Reddy VY, Monir G, Wilber DJ, Lindsay BD, McElderry HT, et al. Paroxysmal AF catheter ablation with a contact force sensing catheter: results of the prospective, multicenter SMART-AF trial. J Am Coll Cardiol. 2014;64:647–56.CrossRefPubMedGoogle Scholar
  21. 21.
    Mohanty S, Natale A, Mohanty P, DI Biase L, Trivedi C, Santangeli P, et al. Pulmonary vein isolation to reduce future risk of atrial fibrillation in patients undergoing typical flutter ablation: results from a randomized pilot study (REDUCE AF). J Cardiovasc Electrophysiol. 2015;26:819–825l.CrossRefPubMedGoogle Scholar
  22. 22.
    Proietti R, Santangeli P, Di Biase L, Joza J, Bernier ML, Wang Y, et al. Comparative effectiveness of wide antral versus ostial pulmonary vein isolation: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2014;7:39–45.CrossRefPubMedGoogle Scholar
  23. 23.
    Bai R, di Biase L, Mohanty P, Santangeli P, Mohanty S, Pump A, et al. Catheter ablation of atrial fibrillation in patients with mechanical mitral valve: long-term outcome of single procedure of pulmonary vein antrum isolation with or without nonpulmonary vein trigger ablation. J Cardiovasc Electrophysiol. 2014;25:824–33.CrossRefPubMedGoogle Scholar
  24. 24.
    Lin D, Santangeli P, Zado ES, Bala R, Hutchinson MD, Riley MP, et al. Electrophysiologic findings and long-term outcomes in patients undergoing third or more catheter ablation procedures for atrial fibrillation. J Cardiovasc Electrophysiol. 2015;26(4):371–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Gokoglan Y, Mohanty S, Gunes MF, Trivedi C, Santangeli P, Gianni C, Asfour I, Bai R, Burkhardt JD, Horton R, Sanchez J, Hao S, Hongo R, Beheiry S, Di Biase L, Natale A. Pulmonary vein antrum isolation in patients with paroxysmal atrial fibrillation: more than a decade of follow-up. Circ Arrhythm Electrophysiol. 2016 9(5) doi:  10.1161/CIRCEP.115.003660
  26. 26.
    Patel D, Mohanty P, Di Biase L, Sanchez JE, Shaheen MH, Burkhardt JD, et al. Outcomes and complications of catheter ablation for atrial fibrillation in females. Heart Rhythm. 2010;7(2):167–72.CrossRefPubMedGoogle Scholar
  27. 27.
    Lee SH, Tai CT, Hsieh MH, Tsao HM, Lin YJ, Chang SL, et al. Predictors of non-pulmonary vein ectopic beats initiating paroxysmal atrial fibrillation: implication for catheter ablation. J Am Coll Cardiol. 2005;46(6):1054–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Sauer WH, Alonso C, McKernan M, et al. Female gender is associated with the presence of nonpulmonary vein triggers of atrial fibrillation (abstr). Circulation. 2003;108 Suppl 5:617.Google Scholar
  29. 29.
    Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988–1028.CrossRefPubMedGoogle Scholar
  30. 30.
    Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670–751.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Ki-Hun Kim
    • 1
  • Sanghamitra Mohanty
    • 2
    • 3
  • Prasant Mohanty
    • 2
  • Chintan Trivedi
    • 2
  • Eli Hamilton Morris
    • 4
  • Pasquale Santangeli
    • 4
  • Rong Bai
    • 2
    • 5
  • Amin Al-Ahmad
    • 2
  • John David Burkhardt
    • 2
  • Joseph G. Gallinghouse
    • 2
  • Rodney Horton
    • 2
    • 6
  • Javier E. Sanchez
    • 2
  • Shane Bailey
    • 2
  • Patrick M. Hranitzky
    • 2
  • Jason Zagrodzky
    • 2
  • Soo G. Kim
    • 7
  • Luigi Di Biase
    • 2
    • 6
    • 7
    • 8
  • Andrea Natale
    • 2
    • 3
    • 6
    • 9
  1. 1.Department of Internal Medicine, Haeundae Paik HospitalInje University College of MedicineBusanSouth Korea
  2. 2.Texas Cardiac Arrhythmia InstituteSt. David’s Medical CenterAustinUSA
  3. 3.Dell Medical SchoolAustinUSA
  4. 4.University of PennsylvaniaPennsylvaniaUSA
  5. 5.Department of Cardiology, Beijing Anzhen HospitalCapital Medical UniversityBeijingChina
  6. 6.Department of Biomedical EngineeringUniversity of Texas at AustinAustinUSA
  7. 7.Albert Einstein College of Medicine at Montefiore HospitalBronxUSA
  8. 8.Department of CardiologyUniversity of FoggiaFoggiaItaly
  9. 9.California Pacific Medical CenterSan FranciscoUSA

Personalised recommendations